CLS granted patent in China for the product and method of controlling treatment with imILT protocol
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) has received a new patent registration in China. The patent is titled "Temp feedback controlled cooled probe" and corresponds to the European patent "Apparatus and Method for Controlling Immunostimulating Laser Thermotherapy" which was granted in 2019.“As with the corresponding patent in Europe, the aim with the China patent is to remove any opportunity for competitors to develop both cooled and non-cooled fiber for our imILT protocol. CLS’s non-cooled fiber has a unique position, and we want to ensure we retain that position,”